2021
Radical Exenteration of the Skull Base for End-Stage, Locally Advanced Sinonasal Malignancies: Challenging the Dictum of Unresectability
Yeung JT, Caminer DM, Young IM, Sughrue ME, Teo C. Radical Exenteration of the Skull Base for End-Stage, Locally Advanced Sinonasal Malignancies: Challenging the Dictum of Unresectability. World Neurosurgery 2021, 150: e102-e107. PMID: 33647490, DOI: 10.1016/j.wneu.2021.02.092.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultCarcinomaCarcinoma, Adenoid CysticChildEsthesioneuroblastoma, OlfactoryFemaleHumansMaleMaxillary Sinus NeoplasmsMiddle AgedNasopharyngeal CarcinomaNeoplasm StagingNeurofibrosarcomaNeurosurgical ProceduresNose NeoplasmsOsteosarcomaParanasal Sinus NeoplasmsProgression-Free SurvivalSalvage TherapySarcomaSkull BaseSquamous Cell Carcinoma of Head and NeckSurvival RateYoung AdultConceptsAdvanced sinonasal cancerSinonasal cancerPerioperative complicationsSalvage surgeryIntracranial involvementSingle-center retrospective reviewAdvanced sinonasal malignanciesAdvanced sinonasal tumorsDetails of chemotherapyRadical salvage surgerySalvage surgical resectionRole of surgeryPrior surgeryOverall survivalPatient demographicsSurgical resectionRetrospective reviewAggressive diseasePalliative careSinonasal malignanciesSurvival outcomesSurgical approachTreatment optionsIntracranial invasionSinonasal tumors
2020
The Surgical Resection of Brainstem Glioma: Outcomes and Prognostic Factors
Faulkner H, Arnaout O, Hoshide R, Young IM, Yeung JT, Sughrue ME, Teo C. The Surgical Resection of Brainstem Glioma: Outcomes and Prognostic Factors. World Neurosurgery 2020, 146: e639-e650. PMID: 33152495, DOI: 10.1016/j.wneu.2020.10.147.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAstrocytomaAtaxiaBrain Stem NeoplasmsCerebrospinal Fluid LeakChildChild, PreschoolDiplopiaEpendymomaFemaleGlioblastomaGliomaHeadacheHumansHydrocephalusInfantInfant, NewbornKaplan-Meier EstimateKarnofsky Performance StatusMachine LearningMagnetic Resonance ImagingMaleMiddle AgedMultivariate AnalysisNauseaNeoplasm GradingNeoplasm, ResidualNeurosurgical ProceduresPostoperative ComplicationsPrognosisRetrospective StudiesSurvival RateTumor BurdenVomitingYoung AdultConceptsBrainstem gliomasSurgical resectionPrognostic factorsSurgical treatmentTransient neurologic deficitsRadical surgical resectionHigh-grade tumorsPostoperative radiographic evaluationMagnetic resonance imagingChart reviewNeurologic deficitsOverall survivalSurgical candidatesConfers survival advantageMedian ageSurgical indicationsPatient selectionSurvival outcomesRadiographic evaluationSelect subgroupRadiographic featuresPrimary treatmentPermanent deficitsSurvival advantageTreatment selectionClinical and economic burden of neurofibromatosis type 2 in the United States
Koo AB, Yeung JT, Freedman IG, Lee JH, Ahmed OM, Ma AK, Miyagishima DF, DiLuna M, Kahle K. Clinical and economic burden of neurofibromatosis type 2 in the United States. Clinical Neurology And Neurosurgery 2020, 197: 106053. PMID: 32683193, DOI: 10.1016/j.clineuro.2020.106053.Peer-Reviewed Original ResearchConceptsOpen resectionPatient demographicsRisk factorsMeningioma resectionMulti-year cross-sectional studyNeurofibromatosis type 2 (NF2) patientsSpine tumor resectionCommon admission diagnosesNational Inpatient SampleType 2 patientsCross-sectional studySignificant independent associationNeurofibromatosis type 2Regression analysisInflation-adjusted costAdmission diagnosisHospital stayDischarge weightIndependent predictorsObstructive hydrocephalusSurgical interventionDiagnosis codesHospital characteristicsInpatient populationInpatient Sample
2012
Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy
Yeung JT, Hamilton RL, Okada H, Jakacki RI, Pollack IF. Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy. Journal Of Neuro-Oncology 2012, 111: 103-111. PMID: 23179498, PMCID: PMC3546121, DOI: 10.1007/s11060-012-0998-x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAgedAged, 80 and overAntigens, NeoplasmBrainBrain NeoplasmsCancer VaccinesChildChild, PreschoolEpendymomaFemaleGene Expression Regulation, NeoplasticHistocompatibility Antigens Class IHumansInfantInhibitor of Apoptosis ProteinsInterleukin-13 Receptor alpha1 SubunitMaleMiddle AgedReceptor, EphA2SurvivinWT1 ProteinsConceptsTumor-associated antigensMore tumor-associated antigensIL-13Rα2Positive stainingAdult ependymomasMultiple peptides vaccineNormal brain tissueGlioma vaccinesImmunotherapy approachesVaccine therapyPediatric casesAdult casesTumor recurrenceClinical trialsPeptide vaccinePediatric ependymomaNormal brainEpendymomaBrain tissuePediatric gliomasTumor 1SurvivinStainingEphA2VaccinePegylated interferon-α-2b for children with recurrent craniopharyngioma.
Yeung JT, Pollack IF, Panigrahy A, Jakacki RI. Pegylated interferon-α-2b for children with recurrent craniopharyngioma. Journal Of Neurosurgery Pediatrics 2012, 10: 498-503. PMID: 23061825, DOI: 10.3171/2012.9.peds12225.Peer-Reviewed Original ResearchConceptsMonths of treatmentGross total resectionPatient experienced recurrenceRecurrent craniopharyngiomaExperienced recurrenceSubtotal resectionComplete responseRadiation therapyUse of PIDisease 19 monthsDisease 6 monthsDisease 10 yearsInterferon α-2bStable diseaseDurable responsesIntralesional administrationCystic tumorTumor sizeTumor responseSubcutaneous injectionCystic componentFurther interventionCraniopharyngiomaRecurrenceSustained exposure